Skip to main content
SpringerLink
Log in

The true costs of administering infliximab to patients with Crohn's disease (CD) are likely to be lower in clinical practice than those reported for charged amounts,

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Ollendorf DA, Lidsky L.Infliximab drug and infusion costs among patients with Crohn's disease in a commercially-insured setting. American Journal of Therapeutics 13: 502-506, No. 6, Nov-Dec 2006

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

The true costs of administering infliximab to patients with Crohn's disease (CD) are likely to be lower in clinical practice than those reported for charged amounts,. Pharmacoecon. Outcomes News 521, 5 (2007). https://doi.org/10.2165/00151234-200705210-00013

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200705210-00013

Keywords

Search

Navigation